SLC5A2 and type 2 diabetes mellitus: The pooled HR was 0.65 [95% CI: 0.15–2.82, p = 0.33], with moderate heterogeneity (I2 = 65.1%) and a wide prediction interval (0.06–7.32), Figure 8C. Due to the limited sample size and wide variability in event rates, no definitive conclusions can be drawn regarding the impact of SGLT2 inhibitors on ACS-related rehospitalization in patients with T2DM.